Table 1.
Population characteristics
| Clinical factors | Pre-COVID (1/1/2017 - 3/12/2020; n=64,849) | Post-COVID (3/13/2020 - 7/31/2020; n=5,035) |
|---|---|---|
| Recipient factors | ||
| Age, y | 53 (41, 63) | 53 (41, 63) |
| Female sex | 39.5% | 38.0% |
| Race | ||
| White | 45.2% | 41.6% |
| African American | 27.0% | 29.4% |
| Hispanic/Latino | 18.6% | 19.5% |
| Other/multiracial | 9.2% | 9.5% |
| Preemptive transplant | 18.9% | 15.7% |
| Time on dialysis, y | 2.4 (0.4, 5.1) | 2.8 (0.7, 5.2) |
| Primary cause of ESRD | ||
| Glumerulonephritis | 27.0% | 25.6% |
| Diabetes | 29.9% | 32.4% |
| Hypertension | 23.0% | 23.9% |
| Others | 20.0% | 18.2% |
| Panel Reactive Antigen | ||
| 0-9 | 54.3% | 50.0% |
| 10-79 | 20.1% | 11.5% |
| 80-89 | 5.0% | 3.8% |
| 90-100 | 20.6% | 34.6% |
| Body mass index, kg/m2 | 27.6 (23.9, 31.8) | 28.1 (24.4, 32.2) |
| Re-transplant | 12.7% | 11.7% |
| Number of HLA-A mismatches | ||
| 0 | 13.8% | 12.7% |
| 1 | 42.6% | 40.9% |
| 2 | 43.6% | 46.4% |
| Number of HLA-B mismatches | ||
| 0 | 8.7% | 7.4% |
| 1 | 30.8% | 27.9% |
| 2 | 60.5% | 64.8% |
| Number of HLA-DR mismatches | ||
| 0 | 17.2% | 16.6% |
| 1 | 48.8% | 48.7% |
| 2 | 34.0% | 34.7% |
| Donor factors | ||
| Age, y | 40 (29, 52) | 39 (29, 50) |
| Female sex | 46.3% | 40.9% |
| Race | ||
| White | 68.6% | 67.1% |
| African American | 12.0% | 13.0% |
| Hispanic/Latino | 14.7% | 15.0% |
| Other/multiracial | 4.6% | 4.8% |
| Type | ||
| Deceased | 68.9% | 82.2% |
| Living | 31.1% | 17.8% |
| Among deceased donors | (n=44,709) | (n=4,139) |
| Cold ischemic time, h | 17.1 (11.7, 22.7) | 16.8 (11.3, 22.3) |
| Donation after circulatory death | 24.1% | 25.1% |
| Donor death due to stroke | 23.0% | 20.4% |
| Pulsatile reperfusion | 42.5% | 44.3% |
| Terminal serum creatinine, mg/dl | 0.9 (0.7, 1.4) | 1.0 (0.7, 1.4) |
ESRD, end-stage renal disease; and HLA, human leukocyte antigen. Numbers indicate median (interquartile range) for continuous variables and percent for categorical variables.